Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (Results from the Society for Cardiac Angiography and Interventions Registry)

American Journal of Cardiology

Volumn 91, Issue 7, 2003, Pages 803-806

  Horwitz, Phillip A ^b   Berlin, Jesse A ^b   Sauer, William H ^b   Laskey, Warren K ^b   Krone, Ronald J ^b   Kimmel, Stephen E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG USE; HEMATOMA; HUMAN; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0344837326     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00012-2     Document Type: Article

References (15)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
2. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
4. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II . Lancet. 349:1997;1422-1428.
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation. 96:1997;1445-1453.
6. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 352:1998;87-92.
7. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894.
8. Laskey W.K., Kimmel S., Krone R.J. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv. 49:2000;19-22.
9. Noto T.J. Jr, Johnson L.W., Krone R., Weaver W.F., Clark D.A., Kramer J.R. Jr, Vetrovec G.W. Cardiac catheterization 1990; a report of the Registry of the Society for Cardiac Angiography and Interventions(SCA&I). Cathet Cardiovasc Diagn. 24:1991;75-83.
10. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 127:1997;757-763.
11. D'Agostino R.B. Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med. 17:1998;2265-2281.
12. Neuhaus J.M., Kalbfleisch J.D. Between- and within-cluster covariate effects in the analysis of clustered data. Biometrics. 54:1998;638-645.
13. Berlin J.A., Kimmel S.E., Ten Have T.R., Sammel M.D. An empirical comparison of several clustered data approaches under confounding due to cluster effects in the analysis of complications of coronary angioplasty. Biometrics. 55:1999;470-476.
14. Cote A.V., Berger P.B., Holmes D.R. Jr, Scott C.G., Bell M.R. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc. 76:2001;890-896.
15. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I. hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.